“Leica Biosystems and Radiometer are solidly into the high single digits here, and we believe that continues for the long term.”

In context

“just elaborate on updated expectations for Radiometer and Leica, and some of the more instrument-heavy focused businesses there, how you're thinking about the back half of the year? Thank you. Rainer M. Blair These continue to be Radiometer and Leica Biosystems, our specialty diagnostics businesses for us that continue to grow in the high single-digit range. We really like what we see there. Continued innovation, continued commercial excellence. I might add the StatLab acquisition that really strengthens Leica Biosystems offering across the entire workflow and provides leverage across that entire workflow. It's very compatible, StatLab, with the existing portfolio. It's 85% consumables. It's got great economics, and we expect that to grow high single digits here in the long term as well. Leica Biosystems and Radiometer are solidly into the high single digits here, and we believe that continues for the long term. Operator Thank you. We will take our last question from Patrick Donnelly with Citi. Please go ahead. Rainer M. Blair Morning, Patrick. Patrick Donnelly Hey, guys. Hey, Rainer. Thanks for taking the question. Maybe another one on the bioprocessing piece. Just in terms of seeing multiple customers all push out within a few weeks of each other, seemingly all into 2027, I guess the confidence that it's just resin, is it not leaking into single use? I guess why would multiple customers all at essentially the same time do this push out? I mean, what were you hearing in terms of, I understand the resins piece, but any other common themes that you were picking up that drove this push out? Rainer M. Blair I wouldn't characterize it as multiple customers. I would really characterize it as a few”